WO1993014777A1 - PEPTIDYL DERIVATIVES AS INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME - Google Patents

PEPTIDYL DERIVATIVES AS INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME Download PDF

Info

Publication number
WO1993014777A1
WO1993014777A1 PCT/US1993/000481 US9300481W WO9314777A1 WO 1993014777 A1 WO1993014777 A1 WO 1993014777A1 US 9300481 W US9300481 W US 9300481W WO 9314777 A1 WO9314777 A1 WO 9314777A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
amino
hydroxy
substituted
aryl
Prior art date
Application number
PCT/US1993/000481
Other languages
French (fr)
Inventor
Kevin T. Chapman
Malcolm Maccoss
William H. Parsons
Original Assignee
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.
Publication of WO1993014777A1 publication Critical patent/WO1993014777A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C245/00Compounds containing chains of at least two nitrogen atoms with at least one nitrogen-to-nitrogen multiple bond
    • C07C245/12Diazo compounds, i.e. compounds having the free valencies of >N2 groups attached to the same carbon atom
    • C07C245/14Diazo compounds, i.e. compounds having the free valencies of >N2 groups attached to the same carbon atom having diazo groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C245/18Diazo compounds, i.e. compounds having the free valencies of >N2 groups attached to the same carbon atom having diazo groups bound to acyclic carbon atoms of a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Definitions

  • This invention relates to substituted peptidyl derivatives useful in the treatment of inflammation in lung, central nervous system, kidney, joints, endocardium, pericardium, eyes, ears, skin, gastrointestinal tract and urogenital system. More particularly, this invention relates substituted peptidyl lactones and open forms thereof that are useful inhibitors of interleukin-1 ⁇ converting enzyme (ICE). Interleukin-1 ⁇ converting enzyme (ICE) has been identified as the enzyme responsible for ICE.
  • ICE Interleukin-1 ⁇ converting enzyme
  • IL-1 ⁇ interleukin-1 ⁇
  • IL-1 Mammalian interleukin-1 (IL-1) is an
  • the primary cell type responsible for IL-1 production is the
  • peripheral blood monocyte Other cell types have also been described as releasing or containing IL-1 or IL-1 like molecules. These include epithelial cells (Luger, et al., J. Immunol. 127: 1493-1498 (1981), Le et al., J. Immunol. 138: 2520-2526 (1987) and Lovett and Larsen, J. Clin. Invest. 82: 115-122 (1988), connective tissue cells (Ollivierre et al., Biochem. Biophys. Res. Comm. 141: 904-911 (1986), Le et al, J. Immunol. 138: 2520-2526 (1987), cells of neuronal origin (Giulian et al., J. Esp. Med. 164:594-604 (1986) and leukocytes (Pistoia et al., J.
  • Biologically active IL-1 exists in two distinct forms, IL-l ⁇ with an isoelectric point of about pI 5.2 and IL-1 ⁇ with an isoelectric point of about 7.0 with both forms having a molecular mass of about 17,500 (Bayne et al., J. Esp. Med. 163:
  • Mammalian IL-1 ⁇ is synthesized as a cell associated precursor polypeptide with a molecular mass of about 31.4 kDa (Limjuco et al., Proc. Natl. Acad. Sci USA 83: 3972-3976 (1986).
  • Precursor IL-1 ⁇ is unable to bind to IL-1 receptors and is
  • Mammalian cells capable of producing IL-1 ⁇ include, but are not limited to, karatinocytes, endothelial cells, mesangial cells, thymic epithelial cells, dermal fibroblasts, chondrocytes, astrocytes, glioma cells, mononuclear phagocytes, granulocytes, T and B lymphocytes and NK cells.
  • interleukin-1 interleukin-1
  • proteolysis inducing factor stimulates muscle cells to. produce
  • IL-1 has multiple effects on cells involved in inflammation and wound healing. Subcutaneous injection of IL-1 leads to margination of neutrophils and maximal extravascular infiltration of the
  • PMN polymorphonuclear leukocytes
  • macrophages have been reported to be chemotactically attracted to IL-1 to produce prostaglandins in response to IL-1 and to exhibit a more prolonged and active tumoricidal state.
  • IL-1 is also a potent bone resorptive agent capable upon infusion into mice of causing
  • disease states in which the ICE inhibitors of Formula I may be useful as therapeutic agents include, but are not limited to, infectious diseases where active infection exists at any body site, such as meningitis and salpingitis;
  • infections including septic shock, disseminated intravascular coagulation, and/or adult respiratory distress syndrome; acute or chronic inflammation due to antigen, antibody, and/or
  • Immune-based diseases which may be responsive to ICE inhibitors of Formula I include but are not limited to conditions involving T-cells and/or macrophages such as acute and delayed hypersensitivity, graft rejection, and graft-versus-host-disease; auto-immune diseases including Type I diabetes mellitus and multiple sclerosis.
  • ICE inhibitors of Formula I may also be useful in the treatment of bone and cartilage
  • ICE inhibitors of Formula I may also be useful in treatment of certain tumors which produce IL 1 as an autocrine growth factor and in preventing the cachexia associated with certain tumors.
  • Novel peptidyl derivatives formula I are found to be potent inhibitors of interleukin-1 ⁇ converting enzyme (ICE).
  • Compounds of formula I are useful in the treatment of deseases including
  • the invention encompasses compounds of formula I..
  • aryl C 1-6 alkyl wherein the aryl group is selected from the group consisting of: (1) phenyl,
  • substitutents are independently C 1-6 alkyl, halo, hydroxy, C 1-6 alkyl amino, C 1-6 alkoxy, C 1-6 alkylthio, and
  • AA 1 is independently selected from the group
  • R 7 is selected from the group
  • aryl is defined as immediately, above, and wherein the aryl may be mono and di-substituted, the substituents being each independently C 1-6 alkyl, halo, hydroxy, C 1-6 alkyl amino, C 1-6 alkoxy,
  • AA 2 is independently selected from the group
  • R 8 and R 9 are each independently selected from the group consisting of
  • aryl is defined as immediately above, and wherein the aryl may be mono and di-substituted, the substituents being each independently C 1-6 alkyl, halo, hydroxy, C 1-6 alkyl amino, C 1-6 alkoxy,
  • AA 1 is independently selected from the group
  • R 7 is aryl C 1-6 alkyl
  • aryl is defined as immediately above, and wherein the aryl may be mono and di-substituted , the substituents being each independently C 1-6 alkyl, halo, hydroxy, C 1-6 alkyl amino, C 1-6 alkoxy,
  • AA 2 is independently selected from the group
  • R 3 and R 9 are each independently selected from the group consisting of
  • aryl is defined as immediately above, and wherein the aryl may be mono and di-substituted, the substituents being each independently C 1-6 alkyl, halo, hydroxy, C 1-6 alkyl amino, C 1-6 alkoxy,
  • AA1, AA2 and AA3 are each independently selected from the group consisting of the L- and D- forms of the amino acids including glycine, alanine, valine, leucine, isoleucine, serine, threonine, aspartic acid, asparagine, glutamic acid, glutamine, lysine, hydroxy-lysine, histidine, arginine, phenylala ⁇ ine, tyrosine, tryptophan, cysteine, methionine,
  • ornithine ß-alanine, homoserine, homotyrosine, homophenylalanine and citrulline.
  • R 1 is C 1-3 alkyl
  • R 8 and R 9 are each individually
  • aryl C 1-6 alkyl wherein the aryl group is selected from phenyl and indolyl, and the aryl group may be substituted with hydroxy, C 1-3 alkyl.
  • R 1 is methyl
  • R 8 is C 1-6 alkyl
  • This invention also concerns to
  • compositions and methods of treatment of interleukin-1 and interleukin-1 ⁇ mediated or implicated disorders or diseases comprising
  • interleukin-1 ⁇ inhibitors of formula (I) as the active constituents.
  • this invention concerns pharmaceutical compositions and methods of treatment of diseases selected from septic shock, allograft rejection, inflammatory bowel disease and rheumatoid arthritis in a patient in need of such treatment comprising:
  • the tetrapeptide diazomethylketone can be prepared as follows. FMOC-aspartic acid ⁇ -methyl ester is converted to its diazomethylketone as before. The FMOC group is then removed with
  • This invention also relates to a method of treatment for patients (including man and/or mammalian animals raised in the dairy, meat, or fur industries or as pets) suffering from disorders or diseases which can be attributed to IL-1/ICE as previously described, and more specifically, a method of
  • IL-1/ICE inhibitors of formula (I) as the active constituents.
  • disease states in which the ICE inhibitors of Formula I may be useful as therapeutic agents include, but are not limited to, infectious diseases where active infection exists at any body site, such as meningitis and salpingitis;
  • infections including septic shock, disseminated intravascular coagulation, and/or adult respiratory distress syndrome; acute or chronic inflammation due to antigen, antibody, and/or
  • Immune-based diseases which may be responsive to ICE inhibitors of Formula I include but are not limited to conditions involving T-cells and/or macrophages such as acute and delayed hypersensitivity, graft rejection, and graft-versus-host-disease; auto-immune diseases including Type I diabetes mellitus and multiple sclerosis.
  • ICE inhibitors of Formula I may also be useful in the treatment of bone and cartilage
  • ICE inhibitors of Formula I may also be useful in treatment of certain tumors which produce IL 1 as an autocrine growth factor and in preventing the cachexia associated with certain tumors.
  • parenteral as used herein
  • warm-blooded animals such as mice, rats, horses, cattle, sheep, dogs, cats, etc.
  • the compounds of the invention are effective in the treatment of humans.
  • compositions containing the active ingredient may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs.
  • Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and
  • Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets.
  • excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc.
  • the tablets may be uncoated or they may be coated by known techniques to delay disintegration and
  • a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated by the techniques described in the U.S. Patents 4,256,108; 4,166,452; and
  • Formulations for oral use may also be
  • the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin, or olive oil.
  • an inert solid diluent for example, calcium carbonate, calcium phosphate or kaolin
  • water or an oil medium for example peanut oil, liquid paraffin, or olive oil.
  • Aqueous suspensions contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions.
  • excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxy-propylmethylcellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring .
  • phosphatide for example lecithin
  • condensation products of an alkylene oxide with fatty acids for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyl-eneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol
  • anhydrides for example polyethylene sorbitan
  • the aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl, p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin.
  • Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin.
  • the oily suspensions may contain a
  • thickening agent for example beeswax, hard paraffin or cetyl alcohol.
  • Sweetening agents such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation.
  • compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
  • Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives.
  • Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example
  • sweetening, flavoring and coloring agents may also be present.
  • compositions of the invention may also be in the form of oil-in-water emulsions.
  • the oily phase may be a vegetable oil, for example olive oil or arachis oil, .or a mineral oil, for example liquid paraffin or mixtures of these.
  • Suitable emulsifying agents may be naturally-occurring gums, for example gum acacia or gum
  • tragacanth naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol
  • anhydrides for example sorbitan monooleate
  • condensation products of the said partial esters with ethylene oxide for example polyoxyethylene sorbitan monooleate.
  • the emulsions may also contain
  • sweetening and flavoring agents are sweetening and flavoring agents.
  • Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents.
  • the pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension. This suspension may be
  • the sterile injectable preparation may also be a sterile
  • injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent for example as a solution in 1,3-butane diol.
  • acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil may be employed including synthetic mono- or diglycerides.
  • fatty acids such as oleic acid find usein the preparation of injectables.
  • the compounds of formula (I) may also be administered in the form of suppositories for rectal administration of the drug.
  • These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
  • suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
  • Such materials are cocoa butter and
  • creams, ointments, jellies, solutions or suspensions, etc., containing the compounds of Formula (I) are employed.
  • topical application shall include mouth washes and gargles.
  • Dosage levels of the order of from about 0.05 mg to about 140 mg per kilogram of body weight per day are useful in the treatment of the above-indicated conditions (about 2.5 mg to about 7 gms. per patient per day).
  • inflammation may be effectively treated by the administration of from about 0.01 to 50 mg of the compound per kilogram of body weight per day (about 0.5 mg to about 3.5 gms per patient per day).
  • a formulation intended for the oral administration of humans may contain from 0.5 mg to 5 gm of active agent compounded with an appropriate and convenient amount of carrier material which may vary from about 5 to about 95 percent of the total
  • Dosage unit forms will generally contain between from about 1 mg to about 500 mg of an active ingredient. It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination and the severity of the particular disease undergoing therapy.

Abstract

Novel peptidyl derivatives of formula (I) are found to be potent inhibitors of interleukin-1β converting enzyme (ICE). Compounds of formula (I) may be useful in the treatment of inflammatory or immune-based diseases of the lung and airways; central nervous system and surrounding membranes; the eyes and ears; joints, bones, and connective tissues; cardiovascular system including the pericardium; the gastrointestinal and urogenital systems; the skin and mucosal membranes. Compounds of formula (I) are also useful in treating the complications of infection (e.g., gram negative shock) and tumors in which IL 1 functions as an autocrine growth factor or as a mediatior of cachexia.

Description

TITLE OF THE INVENTION
PEPTIDYL DERIVATIVES AS INHIBITORS OF INTERLEUKIN-1β
CONVERTING ENZYME
BACKGROUND OF THE INVENTION
This invention relates to substituted peptidyl derivatives useful in the treatment of inflammation in lung, central nervous system, kidney, joints, endocardium, pericardium, eyes, ears, skin, gastrointestinal tract and urogenital system. More particularly, this invention relates substituted peptidyl lactones and open forms thereof that are useful inhibitors of interleukin-1β converting enzyme (ICE). Interleukin-1β converting enzyme (ICE) has been identified as the enzyme responsible for
converting precursor interleukin-1β (IL-1β) to biologically active IL-1β.
Mammalian interleukin-1 (IL-1) is an
immunoregulatory protein secreted by cell types as part of the inflammatory response. The primary cell type responsible for IL-1 production is the
peripheral blood monocyte. Other cell types have also been described as releasing or containing IL-1 or IL-1 like molecules. These include epithelial cells (Luger, et al., J. Immunol. 127: 1493-1498 (1981), Le et al., J. Immunol. 138: 2520-2526 (1987) and Lovett and Larsen, J. Clin. Invest. 82: 115-122 (1988), connective tissue cells (Ollivierre et al., Biochem. Biophys. Res. Comm. 141: 904-911 (1986), Le et al, J. Immunol. 138: 2520-2526 (1987), cells of neuronal origin (Giulian et al., J. Esp. Med. 164:594-604 (1986) and leukocytes (Pistoia et al., J.
Immunol. 136: 1688-1692 (1986), Acres et al., Mol. Immuno. 24: 479-485 (1987), Acres et al., J. Immunol. 138: 2132-2136 (1987) and Lindenmann et al., J.
Immunol 140: 837-839 (1988).
Biologically active IL-1 exists in two distinct forms, IL-lα with an isoelectric point of about pI 5.2 and IL-1β with an isoelectric point of about 7.0 with both forms having a molecular mass of about 17,500 (Bayne et al., J. Esp. Med. 163:
1267-1280 (1986) and Schmidt, J. Esp. Med. 160: 772 (1984). The polypeptides appear evolutionarily conserved, showing about 27-33% homology at the amino acid level (Clark et al., Nucleic Acids Res. 14:
7897-7914 (1986).
Mammalian IL-1β is synthesized as a cell associated precursor polypeptide with a molecular mass of about 31.4 kDa (Limjuco et al., Proc. Natl. Acad. Sci USA 83: 3972-3976 (1986). Precursor IL-1β is unable to bind to IL-1 receptors and is
biologically inactive (Mosley et al., J. Biol. Chem. 262: 2941-2944 (1987). Biological activity appears dependent upon some form of proteolytic processing which results in the conversion of the precursor 31.5 kDa form to the mature 17.5 kDa form. Evidence is growing that by inhibiting the conversion of
precursor IL-1β to mature IL-1β, one can effectively inhibit the activity of interleukin-1.
Mammalian cells capable of producing IL-1β include, but are not limited to, karatinocytes, endothelial cells, mesangial cells, thymic epithelial cells, dermal fibroblasts, chondrocytes, astrocytes, glioma cells, mononuclear phagocytes, granulocytes, T and B lymphocytes and NK cells.
As discussed by J.J. Oppenheim, et al.
Immunology Today, vol. 7(2):45-56 (1986), the
activities of interleukin-1 are many. It has been observed that catabolin, a factor that promotes degradation of cartilage matrix, also exhibited the thymocyte comitogenic activities of IL-1 and
stimulates chondrocytes to release collagenase neutral proteases and plasminogen activator. In addition, a plasma factor termed proteolysis inducing factor stimulates muscle cells to. produce
prostaglandins which in turn leads to proteolysis, the release of amino. acids and, in the long run, muscle wasting, and appears to represent a fragment of IL-1 with fever-inducing, acute phase response and thymocyte co-mitogenic activities. IL-1 has multiple effects on cells involved in inflammation and wound healing. Subcutaneous injection of IL-1 leads to margination of neutrophils and maximal extravascular infiltration of the
polymorphonuclear leukocytes (PMN). In vitro studies reveal IL-1 to be a chemotactic attractant for PMN to activate PMN to metabolize glucose more rapidly to reduce nitroblue tetrazolium and to release their lysozomal enzymes. Endothelial cells are stimulated to proliferate by IL-1 to produce thromboxane, to become more adhesive and to release procoagulant activity. IL-1 also enhances collagen type IV production by epidermal cells, induces osteoblast proliferation and alkaline phosphatase production and stimulates osteoclasts to resorb bone. Even
macrophages have been reported to be chemotactically attracted to IL-1 to produce prostaglandins in response to IL-1 and to exhibit a more prolonged and active tumoricidal state.
IL-1 is also a potent bone resorptive agent capable upon infusion into mice of causing
hypercaleemia and increas in bone resorptive surface as revealed by his to morphometry Sabatini, M. et al., PNAS 85: 5235-5239, 1988.
Accordingly, disease states in which the ICE inhibitors of Formula I may be useful as therapeutic agents include, but are not limited to, infectious diseases where active infection exists at any body site, such as meningitis and salpingitis;
complications of infections including septic shock, disseminated intravascular coagulation, and/or adult respiratory distress syndrome; acute or chronic inflammation due to antigen, antibody, and/or
complement deposition; inflammatory conditions including arthritis, cholangitis, colitis,
encephalitis, endocarditis, glomerulonephritis, hepatitis, myocarditis, pancreatitis, pericarditis, reperfusion injury and vasculitis. Immune-based diseases which may be responsive to ICE inhibitors of Formula I include but are not limited to conditions involving T-cells and/or macrophages such as acute and delayed hypersensitivity, graft rejection, and graft-versus-host-disease; auto-immune diseases including Type I diabetes mellitus and multiple sclerosis. ICE inhibitors of Formula I may also be useful in the treatment of bone and cartilage
resorption as well as diseases resulting in excessive deposition of extracellular matrix. Such diseases include periodonate diseases interstitial pulmonary fibrosis, cirrhosis, systemic sclerosis, and keloid formation. ICE inhibitors of Formula I may also be useful in treatment of certain tumors which produce IL 1 as an autocrine growth factor and in preventing the cachexia associated with certain tumors.
SUMMARY OF THE INVENTION
Novel peptidyl derivatives formula I are found to be potent inhibitors of interleukin-1β converting enzyme (ICE). Compounds of formula I are useful in the treatment of deseases including
inflammation in lung, central nervous system, kidney, joints, endocardium, pericardium, eyes, ears, skin, gastrointestinal tract and urogenital system. DETAILED DESCRIPTION OF THE INVENTION
The invention encompasses compounds of formula I..
Figure imgf000008_0002
or a pharmaceutically acceptable salt thereof thereof wherein Y is :
Figure imgf000008_0001
R1 is
(a) substituted C1-12 alkyl, wherein the substituent is selected from
(1) hydrogen,
(2) hydroxy,
(3 ) halo , and
(4) C1-6alkylcarbonyl ;
(b) aryl C1-6 alkyl wherein the aryl group is selected from the group consisting of: (1) phenyl,
(2) naphthyl,
(3) pyridyl,
(4) furyl,
(5) thienyl,
(6) thiazolyl,
(7) isothiazolyl,
(8) imidazolyl,
(9) benzimidazolyl,
(10) pyrazinyl,
(11) pyπmidyl,
(12) quinolyl,
(13) isoquinolyl,
(14) benzofuryl,
(15) benzothienyl,
(16) pyrazolyl,
(17) indolyl,
(18) purinyl,
(19) isoxazolyl, and
(20) oxazolyl,
and mono and di-substituted aryl as defined above in items (1) to (20) wherein the substitutents are independently C1-6alkyl, halo, hydroxy, C1-6alkyl amino, C1-6alkoxy, C1-6alkylthio, and
C1-6alkylcarbonyl;
AA1 is independently selected from the group
consisting of
(a) a single bond, and (b) an amino acid of formula Al
Figure imgf000010_0001
wherein R7 is selected from the group
consisting of:
(a) hydrogen,
(b) substituted C1-6 alkyl, wherein the
substituent is selected from
(1) hydrogen,
(2) hydroxy,
(3) halo,
(4) -S-C1-4 alkyl
(5) -SH
(6) C1-6 alkylcarbonyl,
(7) carboxy,
O
(8) -CNH2,
(9) amino carbonyl amino,
(10) C1-4 alkylamino, wherein the alkyl moiety is substituted with
hydrogen or hydroxy, and the amino is substituted with hydrogen or CBZ,
(11) guanidino, and
(c) aryl C1-6 alkyl,
wherein aryl is defined as immediately, above, and wherein the aryl may be mono and di-substituted, the substituents being each independently C1-6alkyl, halo, hydroxy, C1-6alkyl amino, C1-6alkoxy,
C1-6alkylthio, and C1-6alkylcarbonyl;
AA2 is independently selected from the group
consisting of
(a) a single bond, and
(b) an amino acid of formula AII
Figure imgf000011_0001
AA3, which are each independently selected from the group consisting of
(a) a single bond, and
(b) an amino acid of formula AIII
Figure imgf000011_0002
wherein R8 and R9 are each independently selected from the group consisting of
(a) hydrogen,
(b) substituted C1-6 alkyl, wherein the substituent is selected from
(1) hydrogen,
(2) hydroxy,
(3) halo, (4) -S-C1-4 alkyl
(5) -SH
(6) C1-6 alkylcarbonyl,
(7) carboxy,
O
(8) -CNH2,
(9) amino carbonyl amino,
(10) C1-4 alkylamino, wherein the alkyl moiety is substituted with
hydrogen or hydroxy, and the amino is substituted with hydrogen or CBZ,
(11) guanidino, and
(c) aryl C1-6 alkyl,
wherein aryl is defined as immediately above, and wherein the aryl may be mono and di-substituted, the substituents being each independently C1-6alkyl, halo, hydroxy, C1-6alkyl amino, C1-6alkoxy,
C1-6alkylthio, and C1-6alkylcarbonyl.
One class of this genus is the compounds wherein:
R1 is
(a) substituted C1-6 alkyl, wherein the
substituent is selected from
(1) hydrogen,
(2) hydroxy,
(3) chloro or fluoro, and
(b) aryl C1-6 alkyl wherein the aryl group is selected from the group consisting of
(1) phenyl,
(2) naphthyl, (3) pyridyl,
(4) furyl,
(5) thienyl,
(6) thiazolyl,
(7) isothiazolyl,
(8) benzofuryl,
(9) benzothienyl,
(10) indolyl,
(11) isooxazolyl, and
(12) oxazolyl,
and mono and di-substituted C1-10aryl as defined above in items (1) to (12) wherein the substitutents are independently C1-4alkyl, halo, and hydroxy;
AA1 is independently selected from the group
consisting of
(a) a single bond, and
(b) an amino acid of formula Al
Figure imgf000013_0001
wherein R7 is aryl C1-6 alkyl
wherein aryl is defined as immediately above, and wherein the aryl may be mono and di-substituted , the substituents being each independently C1-6alkyl, halo, hydroxy, C1-6alkyl amino, C1-6alkoxy,
C1-6alkylthio, and C1-6alkylcarbonyl; AA2 is independently selected from the group
consisting of
(a) a single bond, and
(b) an amino acid of formula AII
Figure imgf000014_0001
AA3, which are each independently selected from the group consisting of
(a) a single bond, and
(b) an amino acid of formula AIII
Figure imgf000014_0002
wherein R3 and R9 are each independently selected from the group consisting of
(a) hydrogen,
(b) C1-6 alkyl, wherein the substituent is selected from
(1) hydrogen,
(2) hydroxy,
(3) halo,
(4) -S-C1-4 alkyl
(5) -SH
(6) C1-6 alkylcarbonyl,
(7) carboxy, O
( 8 ) -CNH2 ,
(9) C1-4 alkylamino, and C1-4 alkyl amino wherein the alkyl moeity is substituted whith an hydroxy, and
(10) guanidino, and
(c) aryl C1-6 alkyl,
wherein aryl is defined as immediately above, and wherein the aryl may be mono and di-substituted, the substituents being each independently C1-6alkyl, halo, hydroxy, C1-6alkyl amino, C1-6alkoxy,
C1-6alkylthio, and C1-6alkylcarbonyl.
Within this class are the compounds wherein AA1, AA2 and AA3, are each independently selected from the group consisting of the L- and D- forms of the amino acids including glycine, alanine, valine, leucine, isoleucine, serine, threonine, aspartic acid, asparagine, glutamic acid, glutamine, lysine, hydroxy-lysine, histidine, arginine, phenylalaήine, tyrosine, tryptophan, cysteine, methionine,
ornithine, ß-alanine, homoserine, homotyrosine, homophenylalanine and citrulline.
Alternatively, within this class are the subclass of compounds wherein
R1 is C1-3alkyl; and
R8 and R9 are each individually
(a) hydrogen,
(b) C1_6alkyl,
(c) mercapto C1-6alkyl,
(d) hydroxy C1-6alkyl,
(e) carboxy C1-6alkyl, (g) aminocarbonyl C1-6alkyl,
(h) mono - or di-C1-6alkyl amino C1-6galkyl,
(i) guanidino C1-6alkyl,
(j) amino-C1-6alkyl or N-substituted
amino-C1-6alkyl wherein the substituent is carbobenzoxy,
(k) carbamyl C1-6alkyl, or
(1) aryl C1-6alkyl, wherein the aryl group is selected from phenyl and indolyl, and the aryl group may be substituted with hydroxy, C1-3 alkyl.
Within this sub-class are the compounds wherein:
R1 is methyl;
R8 is C1-6alkyl; and
R9 is
(a) hydrogen,
(b) C^alkyl,
(d) benzyl,
(e) p-hydroxy-benzyl,
(f ) N-carbobenzoxy-amino-(n-butyl),
(g) carbamylmethyl,
(h) carbamylethyl,
(i) indol-2-yl-methyl,
(j) substituted phenyl C1-6alkyl, wherein the substituent is hydrogen, hydroxy, carboxy, or C1-4alkyl,
(k) substituted indolyl C1-6alkyl, wherein the substituent is hydrogen, hydroxy, carboxy, or C1-4alkyl, or (1) substituted imidazolyl C1-6alkyl wherein the substituent is hydrogen, hydroxy, carboxy, or C1-4alkyl.
Exemplifying the invention are the following compounds:
(a)N-(N-Acetyl-tyrosinyl-valinyl-alaninyl)-3-amino-5-diazo-4-oxopentanoic acid;
(b)N-(N-Acetyl-tyrosinyl-valinyl-ε-CBZ-lysinyl)-3-amino-5-diazo-4-oxopentanoic acid;
(c)N-(N-Acetyl-tyrosinyl-valinyl-lysinyl)-3-amino-5-diazo-4-oxopentanoic acid.
This invention also concerns to
pharmaceutical composition and methods of treatment of interleukin-1 and interleukin-1β mediated or implicated disorders or diseases (as described above) in a patient (including man and/or mammalian animals raised in the dairy, meat, or fur industries or as pets) in need of such treatment comprising
administration of interleukin-1β inhibitors of formula (I) as the active constituents.
Illustrative of these aspects, this invention concerns pharmaceutical compositions and methods of treatment of diseases selected from septic shock, allograft rejection, inflammatory bowel disease and rheumatoid arthritis in a patient in need of such treatment comprising:
administration of an interleukin-1β inhibitor of formula (I) as the active constituent.
Compounds of the instant invention are conveniently prepared using the procedures described generally below and more explicitly described in the Example section thereafter.
Figure imgf000018_0001
The reactions of the scheme proceed as follows. CBZ-aspartic acid β-methyl ester is
converted to the mixed anhydride with isobutyl chloroformate and N-methylmorpholine. Addition of excess diazomethane provides the desired diazomethylketone. Hydrolysis of the ester is
accomplished using triethylamine in methanol and water. The tetrapeptide diazomethylketone can be prepared as follows. FMOC-aspartic acid β-methyl ester is converted to its diazomethylketone as before. The FMOC group is then removed with
diethylamine and the resulting amine coupled to
N-acetyltyrosinyl-valinyl-alanine using dicyclohexyl carbodiimide in the presence of hydroxybenzotriazole and N-methylmorpholine. The ester is then hydrolyzed as before.
The compounds of the instant invention of the formula (I), as represented in the Examples hereinunder shown to exhibit in vitro inhibitory activities with respect to interleukin-1β. In
particular, these compounds have been shown to
inhibit interleukin-1β converting enzyme from
cleaving precusor interleukin-1β as to form active interleukin-1β at a Ki of less than 1 uM.
This invention also relates to a method of treatment for patients (including man and/or mammalian animals raised in the dairy, meat, or fur industries or as pets) suffering from disorders or diseases which can be attributed to IL-1/ICE as previously described, and more specifically, a method of
treatment involving the administration of the
IL-1/ICE inhibitors of formula (I) as the active constituents.
Accordingly, disease states in which the ICE inhibitors of Formula I may be useful as therapeutic agents include, but are not limited to, infectious diseases where active infection exists at any body site, such as meningitis and salpingitis;
complications of infections including septic shock, disseminated intravascular coagulation, and/or adult respiratory distress syndrome; acute or chronic inflammation due to antigen, antibody, and/or
complement deposition; inflammatory conditions including arthritis, cholangitis, colitis,
encephalitis, endocarditis, glomerulonephritis, hepatitis, myocarditis, pancreatitis, pericarditis, reperfusion injury and vasculitis.. Immune-based diseases which may be responsive to ICE inhibitors of Formula I include but are not limited to conditions involving T-cells and/or macrophages such as acute and delayed hypersensitivity, graft rejection, and graft-versus-host-disease; auto-immune diseases including Type I diabetes mellitus and multiple sclerosis. ICE inhibitors of Formula I may also be useful in the treatment of bone and cartilage
resorption as well as diseases resulting in excessive deposition of extracellular matrix such as
interstitial pulmonary fibrosis, cirrhosis, systemic sclerosis, and keloid formation. ICE inhibitors of Formula I may also be useful in treatment of certain tumors which produce IL 1 as an autocrine growth factor and in preventing the cachexia associated with certain tumors.
For the treatment the above mentioned diseases, the compounds of formula (I) may be
administered orally, topically, parenterally, by inhalation spray or rectally in dosage unit
formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles. The term parenteral as used herein
includes subcutaneous injections, intravenous, intramuscular, intracisternal injection or infusion techniques. In addition to the treatment of
warm-blooded animals such as mice, rats, horses, cattle, sheep, dogs, cats, etc., the compounds of the invention are effective in the treatment of humans.
The pharmaceutical compositions containing the active ingredient may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs. Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and
preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc.
The tablets may be uncoated or they may be coated by known techniques to delay disintegration and
absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated by the techniques described in the U.S. Patents 4,256,108; 4,166,452; and
4,265,874 to form osmotic therapeutic tablets for control release. Formulations for oral use may also be
presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin, or olive oil.
Aqueous suspensions contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions. Such
excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxy-propylmethylcellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring .
phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyl-eneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol
anhydrides, for example polyethylene sorbitan
monooleate. The aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl, p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin. Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin. The oily suspensions may contain a
thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation. These
compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives.
Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example
sweetening, flavoring and coloring agents, may also be present.
The pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil, for example olive oil or arachis oil, .or a mineral oil, for example liquid paraffin or mixtures of these. Suitable emulsifying agents may be naturally-occurring gums, for example gum acacia or gum
tragacanth, naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol
anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate. The emulsions may also contain
sweetening and flavoring agents.
Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents. The pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension. This suspension may be
formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may also be a sterile
injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butane diol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find usein the preparation of injectables.
The compounds of formula (I) may also be administered in the form of suppositories for rectal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials are cocoa butter and
polyethylene glycols.
For topical use, creams, ointments, jellies, solutions or suspensions, etc., containing the compounds of Formula (I) are employed. (For purposes of this application, topical application shall include mouth washes and gargles.)
Dosage levels of the order of from about 0.05 mg to about 140 mg per kilogram of body weight per day are useful in the treatment of the above-indicated conditions (about 2.5 mg to about 7 gms. per patient per day). For example, inflammation may be effectively treated by the administration of from about 0.01 to 50 mg of the compound per kilogram of body weight per day (about 0.5 mg to about 3.5 gms per patient per day).
The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. For example, a formulation intended for the oral administration of humans may contain from 0.5 mg to 5 gm of active agent compounded with an appropriate and convenient amount of carrier material which may vary from about 5 to about 95 percent of the total
composition. Dosage unit forms will generally contain between from about 1 mg to about 500 mg of an active ingredient. It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination and the severity of the particular disease undergoing therapy.
The following Examples are intended to illustrate the preparation of compounds of Formula I, and as such are not intended to limit the invention as set forth in the claims appended, thereto.
EXAMPLE 1
N-Benzylo2ycarbonyl-3-amino-5-diazo-4-oxopentanoic acid triethylammoniυm salt.
STEP A
Figure imgf000027_0001
N-Benzyloxycarbonyl-3-amino-5-diazo-4-oxopentanoic acid methyl ester:
To a solution of CBZ-aspartic acid β-methyl ester (971 mg, 3.45 mmol) and 4-methyl morpholine (399 mL, 3.63 mmol) in 5 mL of freshly di stilled dichloromethane at -10°C was added isobutyl
chloroformate (460 mL, 3.43 mmol). After 15 min, the solution was filtered and excess ethereal
diazomethane was added. The mixture was stirred at 0ºC for 1 h and concentrated. The mixture was purified by MPLC on silica-gel (35×350 mm column, eluting with 30% ethyl acetate in hexane) to give the title compound as a pale yellow oil which crystallized on standing: 1H NMR (200 MHz, CDCl3) δ 7.34 (brs, 5H, Ar-H), 5.92 (brd, 1H, NH), 5.12 (s, 1H, CHN2), 5.12 (s, 2H, CH2Ph), 4.58 (m, 1H, CHNCO), 3.67 (s, 3H, CH3O), 3.03 (dd, 1H, CHHCO2), 2.08 (dd, 1H, CHHCO2).
STEP B
Figure imgf000028_0001
N-Benzyloxycarbonyl-3-amino-5-diazo-4-oxopentanoic acid triethylammonium salt:
To a solution of N-Benzyloxycarbonyl-3-amino-5-diazo-4-oxopentanoic acid methyl ester (20 mg) in 2 mL each of methanol and water was added 400 mL of freshly distilled triethylamine. After 6 h at ambient temperature, the solution was concentrated to afford the title compound: 1H NMR (200 MHz, CD3OD) δ 6.6-6.1 (m, 5H, Ar-H), 5.30 (s, 2H, CH2Ph), 5.22 (m, 1H, CHNCO), 3.28 (dd, 2H, CH2CO2), 2.58 (q, 6H, CH2CH3), 1.00 (t, 9H, CH2GH3). EXAMPLE 2
N-(N-Acetyl-tyrosinyl-valinyl-alaninyl)-3-amino-5-diazo-4-oxopentanoic acid triethyl ammonium salt. STEP A
Figure imgf000029_0001
N-Fluorenylmethyloxycarbonyl-3-amino-5-diazo-4-oxopentanoic acid methyl ester:
To a solution of FMOC-aspartic acid β-methyl ester (1.0g, 2.71 mmol) in5 mL of freshly distilled dichloromethane at -10ºC was added 4-methylmorpholine (313 mL, 2.85 mmol) followed by isobutylchloroformate (358 mL, 2.76 mmol). After 15 min, the mixture was filtered and the solids washed with 5 mL of
dichloromethane. To the combined dichloromethane solutions at 0ºC was added excess ethereal
diazomethane. After 2 h, the mixture was
concentrated, diluted with dichloromethane, filtered, and concentrated. The crude product was purified by MPLC on silica-gel (35×350 mm column, using 40% ethyl acetate in hexane as eluent) to afford the title compound as a pale-yellow crystalline solid: 1H NMR (200 MHz, CDCl3) δ 7.76 (d, 2H, J = 7.30 Hz, Ar-H), 7.58 (d, 2H, J = 7.37 Hz, Ar-1), 7.45-7.25 (m, 4H, Ar-H), 5.80 (brd, 1H, NH), 5.35 (s, 1H, CHN2),
4.66-4.40 (m, 3H, CHCH2O, CHNCO), 4.20 (t, 1H, J = 6.04 Hz, CHCH2O), 3.68 (s, 3H, CH3O), 3.03 (dd, 1H, J = 4.44, 17.60 Hz, CHHCO2), 2.65 (dd, 1H, J = 5.08, 17.29 Hz, CHHCO2).
STEP B
Figure imgf000030_0001
3-Amino-5-diazo-4-oxopentanoic acid methyl ester:
To a solution of N-Fluorenylmethyloxy-carbonyl-3-amino-5-diazo-4-oxopentanoic acid methyl ester in 25 mL of acetonitrile was added 25 mL of diethylamine. After 30 min, the mixture was
concentrated. The resulting orange solid was
triturated with dichloromethane, the solid removed by filtration, and the liquid concentrated. The orange oil was purified by MPLC on silica-gel (22×300 mm column, eluting with a gradient of dichloromethane to 17o ammonia and 10% methanol in dichloromethane) to afford the title compound as an orange oil: 1H NMR (200 MHz, CD3OD) δ 3.70 (m, 1H, CHNH2), 3.67 (s, 3H, CH3O), 2.74 (dd, 1H, J = 5.82, 16.5 Hz, CHHCO2), 2.57 (dd, 1H, J = 7.55, 16.6 Hz, CHHCO2). STEP C
Figure imgf000031_0001
N-(N-Acetyltyrosinyl-valinyl-alaninyl)-3-Amino-5-diazo-4-oxopentanoic acid methyl ester:
To a solution of 3-Amino-5-diazo-4-oxopentanoic acid methyl ester (81.3 mg, 0.475 mmol) in 3 mL of DMF was added 4-methylmorpholine (261 mL, 2.38 mmol) followed by acetyltyrosinyl-valinyl-alanine (186 mg, 0.475 mmol). The mixture was cooled to 0ºC, and hydroxybenzotriazole (96 mg, 0.713 mmol) and dicyclohexyl carbodiimide (98 mg, 0.475 mmol) were added. The ice bath was removed and the mixture stirred overnight. The orange suspension was
filtered and purified by Sephadex LH-20®
chromatography to afford 190 mg of the title compound as an orange solid: 1H NMR (200 MHz, DMF-D7) δ
8.4-7.7 (m, NH's), 7.09 (d, 2H, J - 6.98 Hz, Ar-H), 6.73 (d, 2H, J = 8.61 Hz, Ar-H), 6.15 (s, 1H, CHN2), 4.8-4.5 (m, 2H), 4,4-4.2 (m, 2H), 3.63 (s, 3H, CH3O), 3.1-2.6 (m, 4H, CH2Ar, CH2CO2), 2.1 (m, 1H,
CH(CH3)2), 1.86 (s, 3H, CH3CO), 1.37 (d, 1.5H, J = 7.30 Hz, CHCH3 diastereomer A), 1.34 (d, 1.5H, J = 6.84 Hz, CHCH3 diastereomer B), 0.91 (m, 6H, CH(CH3)2 two diastereomers). STEP D
Figure imgf000032_0001
N-(N-Acetyltyrosinyl-valinyl-alaninyl)-3-Amino-5-diazo-4-oxopentanoic acid triethyl ammonium salt:
To a solution of N-(N-Acetyltyrosinyl-valinyl-alaninyl)-3-Amino-5-diazo-4-oxopentanoic acid methyl ester (10 mg) in 2 mL each of methanol and water was added 1 mL of freshly distilled
triethylamine. After 24 h, the solution was
concentrated to afford the title compound as an orange glass: 1H NMR (200 MHz, DMF-D7, 1:1 mixture of diastereomers) δ 7.10 (m, 2H, Ar-H), 6.73 (d, 2H, Ar-H) , 6 .29 (s , 0.5H, CHN2 ) , 6 .14 (s , 0 .5H , CHN2) , 4.7-4.1 (m, 4H), 3.2-2.6 (m, 10H), 2.14 (m, 1H-, CH(CH3)2), 1.95 (s, 1.5H, CH3CO), 1.94 (s, 1.5H, COCH3), 1.4-0.8 (m, 18H, CH(CH3), CH(CH3)2,
N(CH2CH3)3).
The following additional compounds are made in an anologous manner:
N-(N-Acetyl-phenylalaninyl-valinyl-alaninyl)-3- amino-5-diazo-4-oxopentanoic acid;
N-(3-phenylpropionyl-valinyl-alaninyl)-3-amino-5-diazo-4-oxopentanoic acid; and
N-(3-(4-hydroxyphenyl)-valinyl!-alaninyl)- 3-amino-5-diazo-4-oxopentanoic acid. N-(N-Acetyl-phenylalaninyl-valinyl-ε-CBZ-lysinyl )-3-amino-5-diazo-4-oxopentanoic acid ;
N-(3-phenylpropionyl-valinyl-ε-CBZ-lysinyl )-3-amino-5-diazo-4-oxopentanoic acid ; and
N-(3-(4-hydroxyphenyl )-propionyl-valinyl-ε-CBZ-lysinyl )-3-amino-5-diazo-4-oxopentanoic acid .
N-(N-Acetyl-phenylalaninyl-valinyl-lysinyl)-3- amino-5-diazo-4-oxopentanoic acid;
N-(3-phenylpropionyl-valinyl-lysinyl)-3-amino-5-diazo-4-oxopentanoic acid; and
N-(3-(4-hydroxyphenyl)-propionyl-valinyl-lysinyl)-3-amino-5-diazo-4-oxopentanoic acid.

Claims

WHAT IS CLAIMED IS:
1. A compound of formula I
Figure imgf000034_0002
or a pharmaceutically acceptable salt thereof thereof wherein Y is:
Figure imgf000034_0001
R1 is
(a) substituted C1-12 alkyl, wherein the substituent is selected from
(1) hydrogen,
(2) hydroxy,
(3) halo, and
(4) C1-6 alkylcarbonyl;
(b) aryl C1-6 alkyl wherein the aryl group is selected from the group consisting of:
(1) phenyl,
(2) naphthyl, (3) pyridyl,
(4) furyl,
(5) thienyl,
(6) thiazolyl,
(7) isothiazolyl,
(8) imidazolyl,
(9) benzimidazolyl,
(10) pyrazinyl,
(11) pyrimidyl,
(12) quinolyl,
(13) isoquinolyl,
(14) benzofuryl,
(15) benzothienyl,
(16) pyrazolyl,
(17) indolyl,
(18) purinyl,
(19) isoxazolyl, and
(20) oxazolyl,
and mono and di-substituted aryl as defined above in items (1) to (20) wherein the substitutents are independently C1-6alkyl, halo, hydroxy, C1-6alkyl amino, C1-6alkoxy, C1-6alkylthio, and
C1-6alkylcarbonyl;
AA1 is selected from the group consisting of
(a) a single bond, and
(b) an amino acid of formula Al
Figure imgf000036_0001
wherein R7 selected from the group consisting of
(a) hydrogen,
(b) substituted C1-6 alkyl, wherein the
substituent is selected from
(1) hydrogen,
(2) hydroxy,
(3) halo,
(4) -S-C1-4 alkyl,
(5) -SH
(6) C1-6 alkylcarbonyl,
(7) carboxy,
O
(8) -CNH2,
(9) amino carbonyl amino,
(10) C1-4 alkylamino, wherein the alkyl moeity is substituted with
hydrogen or hydroxy, and the amino is substituted with hydrogen or
CBZ,
(11) guanidino, and
(c) aryl C1-6 alkyl,
wherein aryl is defined as immediately above, and wherein the aryl may be mono and di-substituted, the substituents being each independently C1-6alkyl, halo, hydroxy, C1-6alkyl amino, C1-6alkoxy,
C1-6alkylthio, and C1-6alkylcarbbnyl,
wherein the aryl may be mono and di-substituted, the substituents being each independently C1-6alkyl, halo, hydroxy, C1-6alkyl amino, C1-6alkoxy,
C1-6alkylthio, and C1-6alkylcarbonyl;
AA2 is selected from the group consisting of
(a) a single bond, and
(b) an amino acid of formula All
Figure imgf000037_0001
AA3 is selected from the group consisting of
(a) a single bond, and
(b) an amino acid of formula AIII
Figure imgf000037_0002
wherein R8 and R9 are each independently selected from the group consisting of
(a) hydrogen,
(b) substituted C1-6 alkyl, wherein the substituent is selected from
(1) hydrogen,
(2) hydroxy,
(3) halo, (4) -S-C1-4 alkyl,
(5) -SH
(6) C1-6 alkylcarbonyl,
(7) carboxy,
O
(8) -CNH2,
(9) amino carbonyl amino,
(10) C1-4 alkylamino, wherein the alkyl moeity is substituted with
hydrogen or hydroxy, and the amino is substituted with hydrogen or CBZ,
(11) guanidino, and
(c) aryl C1-6 alkyl,
wherein aryl is defined as immediately above, and wherein the aryl may be mono and di-substituted, the substituents being each independently C1-6alkyl, halo, hydroxy, C1-6alkyl amino, C1-6alkoxy,
C1-6alkylthio, and C1-6alkylcarbonyl.
2. A compound according Claim 1 wherein AA1, AA2 and AA3, are each independently selected from the group consisting of the L- and D- forms of the amino acids glycine, alanine, valine, leucine, isoleucine, serine, threonine, aspartic acid, asparagine, glutamic acid, glutamine, lysine, hydroxy-lysine, histidine, arginine, phenylalanine, tyrosine, tryptophan, cysteine, methionine,
ornithine, β-alanine, homoserine, homotyrosine, homophenylalanine and citrulline.
3. A compound of Claim 1 wherein:
R1 is
(a) substituted C1-6 alkyl, wherein the
substituent is selected from
(1) hydrogen,
(2) hydroxy, and
(3) chloro or fluoro,
(b) aryl C1-6 alkyl wherein the aryl group is selected from the group consisting of
(1) phenyl,
(2) naphthyl,
(3) pyridyl,
(4) furyl,
(5) thienyl,
(6) thiazolyl,
(7) isothiazolyl,
(8) benzofuryl,
(9) benzothienyl,
(10) indolyl,
(11) isooxazolyl, and
(12) oxazolyl, and mono and di-substituted C1-10aryl as defined above in items (1) to (12) wherein the substitutents are independently C1-4alkyl, halo, and hydroxy;
AA1 is selected from the group consisting of
(a) a single bond, and
(b) an amino acid of formula Al
Figure imgf000040_0001
wherein R7 is selected from the group consisting of
(a) hydrogen,
(b) substituted C1-6 alkyl, wherein the
substituent is selected from
(1) hydrogen,
(2) hydroxy,
(3) halo,
(4) -S-C1-4 alkyl
(5) -SH
(6) C1-6 alkylcarbonyl,
(7) carboxy,
O
(8) -CNH2,
(9) C1-4 alkylamino, and C1-4
alkylamino wherein the alkyl moeity is substituted whith an hydroxy, and
(10) guanidino, and
(c) aryl C1-6 alkyl, wherein the aryl group is elected from the group consisting of (1) phenyl,
(2) naphthyl,
(3) pyridyl, (4) furyl,
(5) thienyl,
(6) thiazolyl,
(7) isothiazolyl,
(8) benzofuryl,
(9) benzothienyl,
(10) indolyl,
(11) isooxazolyl, and
(12) oxazolyl,
and wherein the aryl may be mono and di-substituted, the substituents being each independently C1-6alkyl, halo, hydroxy, C1-6alkyl amino, C1-6alkoxy,
C1-6alkylthio, and C1-6alkylcarbonyl;
AA2 is selected from the group consisting of
(a) a single bond, and
(b) an amino acid of formula All
Figure imgf000041_0001
wherein R8 is selected from the group consisting of
(a) hydrogen,
(b) substituted C1-6 alkyl, wherein the substituent is selected from
(1) hydrogen,
(2) hydroxy,
(3) halo,
(4) -S-C1-4 alkyl
(5) -SH (6) C1-6 alky1carbonyl,
(7) carboxy,
O
(8) -CNH2,
(9) C1-4 alkylamino, and C1-4
alkylamino wherein the alkyl moeity is substituted whith an hydroxy, and
(10) guanidino, and
(c) aryl C1-6 alkyl,
wherein aryl is defined as immediately above, and wherein the aryl may be mono and di-substituted, the substituents being each independently C1-6alkyl, halo, hydroxy, C1-6alkyl amino, C1-6alkoxy,
C1-6alkylthio, and C1-6alkylcarbonyl.
4. A compound according to Claim 3 wherein AA3 is selected from the group consisting of
(a) a single bond, and
(b) an amino acid of formula AIII
Figure imgf000042_0001
R9 is selected from the group consisting of
(a) hydrogen,
(b) substituted C1-6 alkyl, wherein the substituent is selected from
(1) hydrogen, (2) hydroxy,
(3) halo,
(4) -S-C1-4 alkyl
(5) -SH
(6) C1-6 alkylcarbonyl,
(7) carboxy,
O
(8) -CNH2,
(9) C1-4 alkylamino, and C1-4
alkylamino wherein the alkyl moeity is substituted whith an hydroxy, and
(10) guanidino, and
(c) aryl C1-6 alkyl,
wherein aryl is defined as immediately above, and wherein the aryl may be mono and di-substituted, the substituents being each independently C1-6alkyl, halo, hydroxy, C1-6alkyl amino, C1-6alkoxy,
C1-6alkylthio, and C1-6alkylcarbonyl.
5. A compound according to Claim 4 wherein AA2 is an amino acid of the fromula All
Figure imgf000043_0001
wherein R8 is selected from the group consisting of
(a) hydrogen,
(b) substituted C1-6 alkyl, wherein the substituent is selected from
(1) hydrogen,
(2) hydroxy,
(3) halo,
(4) -S-C1-4 alkyl
(5) -SH
(6) C1-6 alkylcarbonyl,
(7) carboxy,
O
(8) -CNH2,
(9) C1-4 alkylamino, and C1-4
alkylamino wherein the alkyl moeity is substituted whith an hydroxy, and
(10) guanidino, and
(c) aryl C1-6 alkyl,
wherein aryl is defined as immediately above, and wherein the aryl may be mono and di-substituted, the substituents being each independently C1-6alkyl, halo, hydroxy, C1-6alkyl amino, C1-6alkoxy,
C1-6alkylthio, and C1-6alkylcarbonyl; and
AA3 is an amino acid of formula AIII
Figure imgf000045_0001
wherein R9 is selected from the group consisting of
(a) hydrogen,
(b) substituted C1-6 alkyl, wherein the substituent is selected from
(1) hydrogen,
(2) hydroxy,
(3) halo,
(4) -S-C1-4 alkyl
(5) -SH
(6) C1-6 alkylcarbonyl,
(7) carboxy,
O
(8) -CNH2,
(9) C1-4 alkylamino, and C1-4
alkylamino wherein the alkyl moeity is substituted whith an hydroxy, and
(10) guanidino, and
(c) aryl C1-6 alkyl,
wherein aryl is defined as immediately above, and wherein the aryl may be mono and di-substituted, the substituents being each independently C1-6alkyl, halo, hydroxy, C1-6alkyl amino, C1-6alkoxy,
C1-6alkylthio, and C1-6alkylcarbonyl.
6. A compound according to Claim 5 wherein AA1 is a single bond or an amino acid of formula AI
Figure imgf000046_0001
wherein R7 is aryl C1-6 alkyl wherein aryl is defined as
(1) phenyl,
(2) naphthyl,
(3) pyridyl,
(4) furyl,
(5) thienyl,
(6) thiazolyl,
(7) isothiazolyl,
(8) benzofuryl,
(9) benzothienyl,
(10) indolyl,
(11) isooxazolyl, and
(12) oxazolyl,
and wherein the aryl may be mono, and di-substituted, the substituents being each independently C1-6alkyl, halo, hydroxy, C1-6alkyl amino, C1-6alkoxy,
C1-6alkylthio, and C1-6alkylcarbonyl .
7. A compound according to Claim 6 wherein R1 is C1-6alkyl or aryl C1-6 alkyl wherein aryl is phenyl, naphthyl, thienyl, or benzothienyl;
R3 and R9 are each individually
(a) hydrogen,
(b) Cx.ealkyl,
(c) mercapto C1-6alkyl,
(d) hydroxy C1-6alkyl,
(e) carboxy C1-6alkyl,
(g) aminocarbonyl C1-6alkyl,
(h) mono - or di-C1-6alkyl amino C1-6alkyl,
(i) guanidino C1-6alkyl,
(j) amino-C1-6alkyl or N-substituted
amino-C1-6alkyl wherein the substituent is carbobenzoxy, or
(k) aryl C1-6alkyl, wherein the aryl group is selected from phenyl and indolyl, and the aryl group is substituted with hydrogen, hydroxy, C1-3 alkyl.
8. A compound According to Claim 7 wherein: R1 is methyl or phenyl C1-6 alkyl or hydroxy-phenyl C1-6 alkyl;
AA1 is a single bond or an amino acid of formula Al
Figure imgf000047_0001
wherein R7 is
(a) C1-6alkyl;
(b) substituted phenyl C1-3alkyl, wherein the substituent is hydrogen, hydroxy, carboxy, or C1-4alkyl; or
(c) indolyl methyl;
R8 is C1-6alkyl; and
R9 is
(a) hydrogen,
(b) C1-6alkyl,
(c) amino C1-4alkyl,
(d) N-carbobenzoxy-amino-(n-butyl),
(e) carbamylmethyl,
(f) indol-2-yl-methyl, or
(g) substituted phenyl C1-6alkyl, wherein the substituent is hydrogen, hydroxy, carboxy, or C1-4alkyl.
9. A compound according to Claim 8 wherein R9 is
(a) hydrogen,
(b) C1-6alkyl,
(c) amino C1-4alkyl,
(d) N-carbobenzoxy-amino-(n-butyl),
(e) carbamylmethyl,
(f) indol-2-yl-methyl, or
(g) substituted phenyl C1-3alkyl, wherein the substituent is hydrogen or hydroxy.
10. A compound according to Claim 9
wherein R7 is
(a) C1_6alkyl;
(b) substituted phenyl C1-3alkyl, wherein the substituent is hydrogen or hydroxy; or
(c) indolyl methyl.
11. A compound according to Claim 10 wherein R1 is methyl or phenyl C1-6 alkyl or hydroxy-phenyl C1-6 alkyl;
AA1 is a single bond or tyrosinyl, homotyrosinyl, phenylalaninyl, homophenylalaninyl or tryptophanyl; AA2 is
Figure imgf000049_0002
wherein R8 is C1-4 alkyl; and
AA3 is alaninyl, lysinyl or ε-CBZ-lysinyl.
12. A compound according to Claim 11 wherein R1 is phenyl C1-6 alkyl or hydroxy-phenyl C1-6 alkyl; AA1 is a single bond;
AA2 is
Figure imgf000049_0001
wherein R8 is C1-4 alkyl; and
AA3 is alaninyl, lysinyl or ε-CBZ-lysinyl.
13. A compound according to Claim 12 wherein R1 is phenyl ethyl or hydroxy-phenyl ethyl.
14. A compound according to Claim 13 wherein R1 is methyl;
AA1 is tyrosinyl, homotyrosinyl, phenylalaninyl, homophenylalaninyl or tryptophanyl;
AA2 is
Figure imgf000050_0001
wherein R3 is C1-4 alkyl; and
AA3 is alaninyl, lysinyl or ε-CBZ-lysinyϊ.
15. A compound according to Claim 14 wherein R1 is methyl;
AA1 is tyrosinyl;
AA2 is valinyl, leucinyl or isoleucinyl; and
AA3 is alaninyl, lysinyl or ε-CBZ-lysinyl.
16. A compound according to Claim 15 wherein R1 is methyl;
AA1 is tyrosinyl;
AA2 is valinyl;
AA3 is alaninyl, lysinyl or ε-CBZ-lysinyl.
17. A compound selected from the group consisting of:
(a)N-(N-Acetyl-tyrosinyl-valinyl-lysinyl)-3-amino-5-diazo-4-oxopentanoic acid;
(b)N-(N-Acetyl-tyrosinyl-valinyl-ε-CBZ-lysinyl)-3-amino-5-diazo-4-oxopentanoic acid; and
(c)N-(N-Acetyl-tyrosinyl-valinyl-alaninyl)-3- amino-5-diazo-4-oxopentanoic acid.
18. A compound selected from the group consisting of:
(a)N-(N-Acetyl-phenylalaninyl-valinyl-lysinyl)-3- amino-5-diazo-4-oxopentanoic acid;
(b)N-(N-Acetyl-phenylalaninyl-valinyl-ε-CBZ-lysinyl)-3-amino-5-diazo-4-oxopentanoic acid; and
(c)N-(N-Acetyl-phenylalaninyl-valinyl-alaninyl)-3-amino-5-diazo-4-oxopentanoic acid.
19. A compound selected from the group consisting of:
(a)N-(3-phenylpropionyl-valinyl-lysinyl)-3-amino-3-amino-5-diazo-4-oxopentanoic acid;
(b)N-(3-phenylpropionyl-valinyl-ε-CBZ-lysinyl)-3-amino-5-diazo-4-oxopentanoic acid; and
(c)N-(3-phenylpropionyl-valinyl-alaninyl)-3-amino-5-diazo-4-oxopentanoic acid.
20. A compound selected from the group consisting of:
(a)N-(3-(4-hydroxyphenyl)-propionyl-valinyl-lysinyl)-3-amino-5-diazo-4-oxopentanoic acid;
(b)N-(3-(4-hydroxyphenyl)-propionyl-valinyl-ε-CBZ-lysinyl)-3-amino-5-diazo-4-oxopentanoic acid; and
(c)N-(3-(4-hydroxyphenyl)-valinyl-alaninyl)-3-amino-5-diazo-4-oxopentanoic acid.
21. A compound which is
N-(N-Acetyl-tyrosinyl-valinyl-alaninyl)-3-amino-5-diazo-4-oxopentanoic acid.
22. A compound according to Claim 10 wherein R1 is phenyl C1-6 alkyl,
wherein the C1-6 alkyl is subsitiuted and wherein the substitutent is hydrogen, C1-3 alkyl, C1-3 alkoxy, C1-3 alkylcarbonyl, C1-3 alkylthio, C1-3 alkylamino, halo or hydroxy;
AA1 is a single bond;
AA2 is a single bond; and
AA3 is. alaninyl, lysinyl or ε-CBZ-lysinyl
23. A compound according to Claim 22 wherein R1 is phenylmethyl, phenylethyl,
phenylpropyl, phenylbutyl, phenylpentyl, or
phenylhexyl wherein the methyl, ethyl, propyl, butyl, pentyl, or hexyl, is substituted as defined above.
24 A pharmaceutical composition for treatment interleukin-1 mediated disorders or
diseases in a patient in need of such treatment comprising administration of an interluekin-1β inhibitor according to Claim 1 as the active
constituent.
25 A method of treatment of Interleukin-1 mediated disorders or diseases in a patient in need of such treatment comprising:
administration of an interluekin-1β inhibitor
according to Claim 1 as the active constituent.
PCT/US1993/000481 1992-01-31 1993-01-21 PEPTIDYL DERIVATIVES AS INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME WO1993014777A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83016292A 1992-01-31 1992-01-31
US830,162 1992-01-31

Publications (1)

Publication Number Publication Date
WO1993014777A1 true WO1993014777A1 (en) 1993-08-05

Family

ID=25256441

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/000481 WO1993014777A1 (en) 1992-01-31 1993-01-21 PEPTIDYL DERIVATIVES AS INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME

Country Status (2)

Country Link
AU (1) AU3479593A (en)
WO (1) WO1993014777A1 (en)

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995035308A1 (en) * 1994-06-17 1995-12-28 Vertex Pharmaceuticals Incorporated INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME
US5656627A (en) * 1994-06-17 1997-08-12 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5776718A (en) * 1995-03-24 1998-07-07 Arris Pharmaceutical Corporation Reversible protease inhibitors
US5843904A (en) * 1995-12-20 1998-12-01 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1βconverting enzyme
US5847135A (en) * 1994-06-17 1998-12-08 Vertex Pharmaceuticals, Incorporated Inhibitors of interleukin-1β converting enzyme
US5874424A (en) * 1995-12-20 1999-02-23 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US5968927A (en) * 1996-09-20 1999-10-19 Idun Pharmaceuticals, Inc. Tricyclic compounds for the inhibition of the ICE/ced-3 protease family of enzymes
US5976858A (en) * 1994-02-25 1999-11-02 Arris Pharmaceuticals Irreversible cysteine protease inhibitors containing vinyl groups conjugated to electron withdrawing groups
US6008217A (en) * 1995-12-20 1999-12-28 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US6054487A (en) * 1997-03-18 2000-04-25 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
US6184244B1 (en) 1996-12-16 2001-02-06 Idun Pharmaceuticals, Inc. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US6204261B1 (en) 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
US6288037B1 (en) 1996-01-29 2001-09-11 Basf Aktiengesellschaft Substrates and inhibitors for cysteine protease ICH-1
US6372885B1 (en) 1996-10-22 2002-04-16 Peptide Therapeutics Limited Solid-phase technology for the preparation of amides
US6426413B1 (en) 1998-03-09 2002-07-30 Vertex Pharmaceuticals Incorporated Inhibitors of caspases
US6531474B1 (en) 1998-03-19 2003-03-11 Vertex Pharmaceuticals Incorporated Inhibitors of caspases
US7153822B2 (en) 2002-01-29 2006-12-26 Wyeth Compositions and methods for modulating connexin hemichannels
US7288624B2 (en) 1994-06-17 2007-10-30 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US7417029B2 (en) 2000-05-19 2008-08-26 Vertex Pharmaceuticals Incorporated Prodrug of an ice inhibitor
US7531570B2 (en) 2004-05-27 2009-05-12 Vertex Pharmaceuticals Incorporated Treatment of diseases using ICE inhibitors
EP2241328A1 (en) 2000-05-12 2010-10-20 Immunex Corporation Interleukin-1 inhibitors in the treatment of diseases
US9116157B2 (en) 2010-11-05 2015-08-25 Brandeis University Ice-cleaved alpha-synuclein as a biomarker
US9352010B2 (en) 2011-07-22 2016-05-31 The J. David Gladstone Institutes Treatment of HIV-1 infection and AIDS
EP3603634A1 (en) 2004-05-18 2020-02-05 Novartis AG Pharmaceutical composition containing glycopyrrolate and a beta2 adrenoceptor agonist
US11021514B2 (en) 2016-06-01 2021-06-01 Athira Pharma, Inc. Compounds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991015577A1 (en) * 1990-04-04 1991-10-17 Black, Roy, A. INTERLEUKIN 1'beta' PROTEASE

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991015577A1 (en) * 1990-04-04 1991-10-17 Black, Roy, A. INTERLEUKIN 1'beta' PROTEASE

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF BIOLOGICAL CHEMISTRY, Volume 265, No. 24, issued 25 August 1990, SLEATH et al., "Substrate Specificity of the Protease that Processes Human Interleukin-1B", pages 14526-14528. *

Cited By (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5976858A (en) * 1994-02-25 1999-11-02 Arris Pharmaceuticals Irreversible cysteine protease inhibitors containing vinyl groups conjugated to electron withdrawing groups
US6287840B1 (en) 1994-02-25 2001-09-11 Axys Pharmaceuticals, Inc. Irreversible cysteine protease inhibitors containing vinyl groups conjugated to electron withdrawing groups
WO1995035308A1 (en) * 1994-06-17 1995-12-28 Vertex Pharmaceuticals Incorporated INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME
EP1394175A1 (en) * 1994-06-17 2004-03-03 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1beta converting enzyme
US5716929A (en) * 1994-06-17 1998-02-10 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
EP2123665A2 (en) 1994-06-17 2009-11-25 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1Beta converting enzyme
US7772366B2 (en) 1994-06-17 2010-08-10 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
CZ298625B6 (en) * 1994-06-17 2007-11-28 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1 beta converting enzyme, method of their selection and pharmaceutical compositions in which the inhibitors are comprised
US7288624B2 (en) 1994-06-17 2007-10-30 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US5847135A (en) * 1994-06-17 1998-12-08 Vertex Pharmaceuticals, Incorporated Inhibitors of interleukin-1β converting enzyme
US5756466A (en) * 1994-06-17 1998-05-26 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5656627A (en) * 1994-06-17 1997-08-12 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US6025147A (en) * 1994-06-17 2000-02-15 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1 β converting enzyme
AP797A (en) * 1994-06-17 2000-01-07 Vertex Pharma Inhibitors of interleukin-1B converting enzyme.
US6103711A (en) * 1994-06-17 2000-08-15 Vertex Pharmaceuticals, Incorporated Inhibitors of interleukin-1β converting enzyme
US5776718A (en) * 1995-03-24 1998-07-07 Arris Pharmaceutical Corporation Reversible protease inhibitors
EP2083014A2 (en) 1995-12-20 2009-07-29 Vertex Pharmceuticals Incorporated Inhibitors of interleukin-1ß converting enzyme
US6008217A (en) * 1995-12-20 1999-12-28 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US5843904A (en) * 1995-12-20 1998-12-01 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1βconverting enzyme
US6162790A (en) * 1995-12-20 2000-12-19 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US6204261B1 (en) 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
US7790713B2 (en) 1995-12-20 2010-09-07 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
EP2295442A2 (en) 1995-12-20 2011-03-16 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1beta converting enzyme
US6423840B1 (en) 1995-12-20 2002-07-23 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US5874424A (en) * 1995-12-20 1999-02-23 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US8119631B2 (en) 1995-12-20 2012-02-21 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US6258948B1 (en) 1995-12-20 2001-07-10 Vertex Pharmaceuticals, Incorporated Inhibitors of Interleukin-1β converting enzyme
US6288037B1 (en) 1996-01-29 2001-09-11 Basf Aktiengesellschaft Substrates and inhibitors for cysteine protease ICH-1
US6444663B2 (en) 1996-09-20 2002-09-03 Idun Pharmaceuticals, Inc. Tricyclic compounds for the inhibition of the ICE/ced-3 protease family of enzymes
US5968927A (en) * 1996-09-20 1999-10-19 Idun Pharmaceuticals, Inc. Tricyclic compounds for the inhibition of the ICE/ced-3 protease family of enzymes
US6187771B1 (en) 1996-09-20 2001-02-13 Idun Pharmaceuticals, Inc. Tricyclic compounds for the inhibition of the ICE/ced-3 protease family of enzymes
US6372885B1 (en) 1996-10-22 2002-04-16 Peptide Therapeutics Limited Solid-phase technology for the preparation of amides
US6489353B2 (en) 1996-12-16 2002-12-03 Idun Pharmaceuticals, Inc. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US6184244B1 (en) 1996-12-16 2001-02-06 Idun Pharmaceuticals, Inc. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US6054487A (en) * 1997-03-18 2000-04-25 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
US6426413B1 (en) 1998-03-09 2002-07-30 Vertex Pharmaceuticals Incorporated Inhibitors of caspases
US6531474B1 (en) 1998-03-19 2003-03-11 Vertex Pharmaceuticals Incorporated Inhibitors of caspases
US7358273B2 (en) 1998-03-19 2008-04-15 Vertex Pharmaceuticals Incorporated Inhibitors of caspases
EP2011800A2 (en) 1998-03-19 2009-01-07 Vertex Pharmaceuticals Incorporated Inhibitors of caspase
US8691848B2 (en) 1998-03-19 2014-04-08 Vertex Pharmaceuticals Incorporated Inhibitors of caspases
EP2261233A2 (en) 1998-03-19 2010-12-15 Vertex Pharmaceuticals Incorporated Inhibitors of caspases
EP2261234A2 (en) 1998-03-19 2010-12-15 Vertex Pharmaceuticals Incorporated Inhibitors of caspases
EP2261235A2 (en) 1998-03-19 2010-12-15 Vertex Pharmaceuticals Incorporated Inhibitors of caspases
EP2261232A2 (en) 1998-03-19 2010-12-15 Vertex Pharmaceuticals Incorporated Inhibitors of caspases
EP2241328A1 (en) 2000-05-12 2010-10-20 Immunex Corporation Interleukin-1 inhibitors in the treatment of diseases
US8022041B2 (en) 2000-05-19 2011-09-20 Vertex Pharmaceuticals Incorporated Prodrug of an ICE inhibitor
US9156880B2 (en) 2000-05-19 2015-10-13 Vertex Pharmaceuticals Incorporated Prodrug of an ice inhibitor
US9994613B2 (en) 2000-05-19 2018-06-12 Vertex Pharmaceuticals Incorporated Prodrug of an ICE inhibitor
US9487555B2 (en) 2000-05-19 2016-11-08 Vertex Pharmaceuticals Incorporated Prodrug of an ice inhibitor
US8329662B2 (en) 2000-05-19 2012-12-11 Vertexd Pharmaceuticals Incorporated Prodrug of an ICE inhibitor
US7417029B2 (en) 2000-05-19 2008-08-26 Vertex Pharmaceuticals Incorporated Prodrug of an ice inhibitor
EP2270005A1 (en) 2000-05-19 2011-01-05 Vertex Pharmceuticals Incorporated Prodrug of an ice inhibitor
US7153822B2 (en) 2002-01-29 2006-12-26 Wyeth Compositions and methods for modulating connexin hemichannels
EP3603634A1 (en) 2004-05-18 2020-02-05 Novartis AG Pharmaceutical composition containing glycopyrrolate and a beta2 adrenoceptor agonist
US7531570B2 (en) 2004-05-27 2009-05-12 Vertex Pharmaceuticals Incorporated Treatment of diseases using ICE inhibitors
US9116157B2 (en) 2010-11-05 2015-08-25 Brandeis University Ice-cleaved alpha-synuclein as a biomarker
US9352010B2 (en) 2011-07-22 2016-05-31 The J. David Gladstone Institutes Treatment of HIV-1 infection and AIDS
US9956260B1 (en) 2011-07-22 2018-05-01 The J. David Gladstone Institutes Treatment of HIV-1 infection and AIDS
US11021514B2 (en) 2016-06-01 2021-06-01 Athira Pharma, Inc. Compounds

Also Published As

Publication number Publication date
AU3479593A (en) 1993-09-01

Similar Documents

Publication Publication Date Title
EP0627926B1 (en) PEPTIDYL DERIVATIVES AS INHIBITORS OF INTERLEUKIN-1$g(b) CONVERTING ENZYME
WO1993014777A1 (en) PEPTIDYL DERIVATIVES AS INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME
EP0547699A1 (en) Peptidyl derivatives as inhibitors of interleukin-1B converting enzyme
US5866545A (en) Substituted ketone derivatives as inhibitors of interleukin-1β converting enzyme
US5434248A (en) Peptidyl derivatives as inhibitors of interleukin-1β converting enzyme
DE69531990T2 (en) BICYCLIC LACTAMINE HIBITOR OF THE INTERLEUKIN-1-BETA-CONVERTING ENZYME
RU2067585C1 (en) Derivatives of 5-amino-4-hydroxyhexanoic acid and a method of their synthesis
DE69532113T2 (en) PYRIMIDINE DERIVATIVES AS INTERLEUKIN INHIBITORS
DE69925268T2 (en) Dipeptide caspase inhibitors and their use
KR20000064454A (en) Inhibitors of Interleukin-1beta Converting Enzyme
FR2609289A1 (en) NOVEL COMPOUNDS WITH ACTIVITY OF COLLAGENASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
WO1998049190A2 (en) Substituted oxadiazole cysteine protease inhibitors
SK1022002A3 (en) Prodrug of an ice inhibitor
HU204286B (en) Process for producing renin-inhibiting dipeptide derivatives and pharmaceutical compositions containing them as active components
US5411985A (en) Gamma-pyrone-3-acetic acid as an inhibitor or interleukin-1 β inventory enzyme
US6835714B1 (en) Heterocyclic compounds, intermediates thereof and elastase inhibitors
AU3965199A (en) Cysteine protease inhibitors
EP0623143A1 (en) Substituted phosphinic acid-containing peptidyl derivatives as antidegenerative agents
US4857507A (en) Angiotensinogen analogs
DE69833646T2 (en) (3R) -3-AMINO-4-CARBOXYBUTYRALDEHYDE DERIVATIVES INHIBITING IL-1 / BETA RELEASE
WO1988005049A1 (en) Novel compounds
JPH07173142A (en) Cyclic renin inhibitor containing 3(s)-amino-4-cyclohexyl- 2(r)-hydroxybutyric acid, 4-cyclohexyl-(2r, 3s)- dihydroxybutyric acid or related homologue
MXPA00010379A (en) Cysteine protease inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BB BG BR CA FI HU JP KR LK MG MN MW NO NZ PL RO RU SD US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA